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Abstract The efforts of the topical microbicide field to
identify a safe and effective topical microbicide were
realized in July of 2010 with the reporting of the results
of the Centre for the AIDS Programme of Research in
South Africa 004 trial. In this trial, a 1% tenofovir gel
was found to reduce women’s risk for HIV acquisition by
39% compared to placebo. To understand the impact of
this trial on future microbicide development, we must
view it from the historical perspective of previous phases
2 and 3 clinical trials with detergents and sulfated
polyanions. This knowledge and emerging information
must then be parlayed into the next steps needed to
create a safe, effective, and acceptable topical micro-
bicide. This review will look at the lessons learned from
preclinical and clinical development of topical micro-
bicides, focusing on two significant future challenges: (1)
topical microbicide formulation safety and (2) the critical
role that adherence to product use has in determining
safety and efficacy in clinical trials and ultimately
commercial viability of the licensed product. In addition
to framing these issues within our current understanding
of formulation and prevention of HIV acquisition, recent
advances in our understanding of the mechanism of HIV
transmission and how it informs on future formulation




A topical microbicide, for the purposes of this review, will
be defined as a strategy to prevent the transmission of HIV
at the genital (vaginal and/or penile) and/or gastrointestinal
(GI; rectal) mucosa. To be successful, a topical microbicide
must be delivered in a safe and efficacious manner. The
microbicide must also be acceptable to all users (men and
women) promoting adherence, while optimizing access and
ease of use. The road to a potentially safe and effective
microbicide has been rocky with multiple consecutive
clinical failures of six distinct products.
Modeling studies have predicted that a 60% effective
microbicide with 20% coverage could prevent 2.5 million
new infections in 3 years [1, 2]. This along with promising
nonhuman primate (NHP) vaginal simian–human immuno-
deficiency virus (SHIV)/simian immunodeficiency virus
(SIV) transmission studies demonstrating that vaginally
applied antiretroviral drugs can prevent HIV infection [3, 4]
have resulted in a continued resolve to pursue development
of a safe, effective, and acceptable topical microbicide. In
July 2010, the announcement of the results of the Centre for
the AIDS Programme of Research in South Africa
(CAPRISA) 004 phase 2B clinical trial [5] was the next
step in achieving this goal, and it provided the critically
needed proof that prevention of HIV transmission could be
accomplished with a topical microbicide strategy.
The design of the CAPRISA 004 clinical trial was built
upon previous clinical trial designs using an antiretroviral
(ARV) drug with proven antiviral activity (1% tenofovir
gel) and a unique coitally associated dosing strategy
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DOI 10.1007/s13346-011-0034-2(BAT24, one application of gel no more than 12 h before
intercourse and an additional application of gel within 12 h
post-intercourse with no more than two applications per
day). This regimen resulted in statistically significant (39%)
protection of women from HIV infection. Although not
statistically significant, analysis of individual use subsets
suggested that high gel use/adherence (~50% to 80% of
time) was associated with potentially greater efficacy
(54%). The proof of concept provided by CAPRISA 004
has opened the door to development of a women-initiated
vaginally applied prevention method that could address the
harsh reality of the AIDS pandemic of approximately 7,000
new infections a day with greater than 50% of the new
infections in women, with young women and girls
especially at risk [6].
Lubricants versus medicines versus microbicides
A critical feature of any topical microbicide approach is that
it must be able to protect healthy men and women without
harm following a variety of use patterns that encompass
both periodic and continuous use over the normal span of
sexual activity under a variety of risk situations. There are a
number of commercial and over-the-counter (OTC) prod-
ucts women and men have used in the context of their
sexual activity, but without the intention of preventing HIV
infection/transmission. Thus, it is important to discuss our
knowledge in regard to lubricant and medicine use in the
context of topical microbicide prevention and delivery
strategies.
Many of the sexual lubricants and some vaginal medicines
usedtodayareOTCproductsandarepresumedsafe,ifusedas
directed. Both OTC lubricant and medicine use arises from
individuals seeking relief from irritation and/or a medical
symptom. Lubricant use may also be a choice for enhancing
sexual pleasure. Safety issues arising from the use of these
products are usually mild—deriving from pre-existing aller-
gies to components and/or resulting from improper use
(indication and/or frequency). Because there may already be
anestablishedpatternofOTClubricantusebyindividualsand
populations, they are often considered for use as vehicles to
deliver vaginal, rectal, or penile products, such as micro-
bicides. However, OTC lubricants often have very limited or
no clinical evidence to demonstrate any effect on sexually
transmitted infections (STI). Thus, the historical and current
conundrum for use of OTC lubricants as vehicles or starting
points for microbicide formulation is that although these
products have a demonstrated level of safety when applied to
or used in the genital and/or GI tract, these products were
developed for other indications. Therefore, an assumption of
OTC vehicle safety when used to deliver a product designed
to prevent HIVor STI infection may be not be valid.
Individual components of OTC lubricants, such as
glycerin and polyquaternium-32, have been reported to
possess anti-HIV activity in vitro at the concentrations
used in the products [7, 8]. However, recent data have
suggested that some lubricants can have significant safety
issues in vitro and potentially in vivo. Dezzutti et al. have
reported that vaginal lubricants with high osmolarities are
toxic in vitro and must be diluted substantially to reduce
cytotoxicity (Microbicides 2010, Abstract #347). These
data are in line with the in vivo rectal observations of
Fuchs et al. [9] who have shown that hyperosmotic OTC
lubricants can cause disruption of the GI epithelium.
Moench et al. [10] have linked potential vaginal epithelial
damage by OTC lubricants and common formulation
excipients to increased susceptibility to herpes simplex
virus (HSV) infection in a murine model. In this model,
mice are challenged with a suboptimal inoculum of HSV
3 days after a single intravaginal 12-h exposure to the
microbicide. Enhancement of HSV infection is the result
of increased susceptibility to infection arising from toxic
effects or alterations of the vaginal mucosa. K-Y®
Warming Jelly, the microbicide glycerol monolaurate
(GML), and the humectants/solvents—propylene glycol
and PEG 8—were found to significantly increase suscep-
tibility to infection (>10-fold). The excipients glycerol
(30%, but not 10%) and disodium EDTA (0.1%, but not
0.0186%) were found to increase HSV susceptibility in a
dose-dependent manner, whereas other common exci-
pients (propylene glycol (10%), methylparaben (0.18%),
propylparaben (0.02%), and benzyl alcohol (1%)) did not
alter susceptibility to HSV infection. In contrast, GML
delivered in K-Y® Warming Jelly and administered
vaginally once daily for 3 months or twice daily for
2 months to rhesus macaques did not result in any safety
issues (vaginal irritation) [11]. Furthermore, subsequent
SIV challenge studies GML prevented SIV infection [12].
Finally, at Microbicides 2010, Dr. P. Gorbach presented the
results of a rectal behavioral practices study (Abstract # 348)
which identified a potential linkage between rectal lubricant
use and rectal STI acquisition in men and women. These
results suggest that future microbicide formulation develop-
ment must carefully evaluate the safety of products and not
assume that use of a previously used vehicle or inclusion of
Food and Drug Administration (FDA) identified generally
regarded as safe (GRAS) excipient equates to safety in the
context of prevention of HIVacquisition.
In contrast to OTC lubricants, vaginal and rectal
medicines are regulated by the FDA and follow specific
guidelines that recommend substantial animal and human
safety data for its intended use and any potential off-label
use, e.g., vaginal microbicide used rectally. It is important
to note that extensive safety data are collected not only
during the pre-market but also during the post-marketing
Drug Deliv. and Transl. Res. (2011) 1:194–200 195phase of medicine licensure. Unless there is a profound
effect on HIV or STI acquisition, it is possible more
subtle effects on susceptibility to infection may be
overlooked. Additionally, since medicines have a thera-
peutic intent, side effects such as mucosal irritation,
effects on innate and adaptive immunity, and/or alterations in
beneficial populations of the microbiota, which might signal
significant safety concerns for a topical microbicide strategy,
maynotbeconsideredsignificantintermsofthebenefitofthe
drug to the patient. An example of this point is the use of
vaginal antibiotic creams/gels for bacterial vaginosis. Along
with targeting the vaginosis organisms, the antibiotics may
have a significant impact on the normal vaginal microbiota,
such as H2O2 producing Lactobacilli sp. [13]. Bacterial
vaginosis, which results in a reduction in the presence of
H2O2 producing Lactobacillus sp. in the female reproductive
tract, has been prospectively correlated with increased
susceptibility to HIV infection [14–16]. Thus, again, care
needs to be taken when translating medicinal delivery
vehicles to microbicide use and STI prevention.
Ideal properties of a microbicide
For microbicides, it is hoped that they will ultimately be
available as an OTC product. However, the initial microbicide
strategy(vehicle+activepharmaceuticalingredient(API))will
be regulated by the FDA as a new drug product and will thus
require substantial safety data to move toward product
licensure. Although the FDA has not provided a specific
guidance for development of microbicides, they have (through
presentations to microbicide audiences and publication of
white papers) discussed the ideal properties of a microbicide
and outlined steps for preclinical and nonclinical development
[17, 18]. In addition, since most microbicide strategies can be
reduced to an API + vehicle for regulatory considerations,
many FDA guidances can be adapted to microbicide
development, e.g., antiviral product development [19]a n d
required investigational new drug application content [20].
Preclinical/nonclinical microbicide candidate selection
and the studies required to meet the regulatory requirements
for developing a topical microbicide were recently
reviewed by Doncel and Clark [21]. Therefore, this review
will concentrate on the ideal properties of a microbicide and
how its formulation may contribute to defining these ideal
properties. For the purposes of discussion, I will divide the
properties into four general categories: (1) safety, (2)
nonclinical efficacy, (3) acceptability, and (4) feasibility of
manufacture and production.
Safety A formulation must demonstrate in vitro and in vivo
safety, with minimal or no systemic and local toxicity. This
includes demonstrating a lack of effect on the normal
microbiota found at target mucosal sites, e.g., H2O2
producing Lactobacillus sp. If the microbicide is being
developed for vaginal use, then it should also demonstrate
safety when used rectally to address potential off-label
rectal use of the vaginal product. Additionally, the micro-
bicide and its formulation should not impact the safety of
other therapeutic, STI prevention, or conception (barrier
and hormonal) methods that may be used concurrently with
the microbicide.
Nonclinical efficacy The second set of features are those
related to nonclinical efficacy (also called preclinical). This
includes determining efficacy in vitro on cell lines and
primary cells and ex vivo efficacy in cervicovaginal, penile,
and/or rectal explants. Although not required by the FDA,
animal model efficacy can be used as a potential proof-of-
biological plausibility, if desired. As we have learned from
a number of preclinical and clinical studies, the demonstra-
tion of activity in the presence of semen/seminal fluid,
cervicovaginal, and rectal fluids/secretions and cervical
mucus are critical factors in determining and possibly
predicting potential in vivo issues that will impact clinical
efficacy [22, 23]. The transition from ~pH 4.0 to ~pH 7.0
that occurs in the vagina following exposure to semen can
also represent a barrier to microbicide efficacy, if the
microbicide candidate is unstable and loses efficacy as a
function of pH. Candidates with pH instability are usually
eliminated early in preclinical development or it is
addressed during formulation.
Acceptability A third ideal property is incorporation of
properties and characteristics that will enhance acceptability
and ultimately adherence to the microbicide strategy. The
personal preference decision for initial, consistent, contin-
uous, and/or episodic use of a product is critical to the
ultimate impact of a prevention strategy on the individual
and pandemic level. As has been proposed by Morrow and
Hendrix, the rheological and biochemical properties of gels,
vaginal rings, and other delivery strategies need to be
related to determinants of individual acceptability in order
to increase the probability they will be used [24]. Thus, the
relationship between formulation/vehicle biophysical and
rheological parameters and potential product preference
parameters such as formulated product color, odor, feel,
taste, ease of use, and impact on intercourse (positive or
negative) need to be a critical part of the preclinical and
clinical development of microbicides and the strategies
used to deliver them.
Feasibility of manufacture and production Finally, we need
to address ideal properties associated with feasibility of
production and manufacture of the formulated candidate.
For this property, we must consider both the active
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Formulation production and manufacture must be feasible,
allowing for the production of both the final formulation
and the API in the amounts needed to meet projected needs
(potentially billions of doses). Both the API and final
formulation must meet good manufacturing practices
requirements to assure consistency and quality of the
product. Feasibility of manufacture also encompasses the
production of a product (formulation, delivery device, and
API) with sufficient stability to allow use without signifi-
cant cold-chain, packaging, and/or distribution issues that
would impact its use by at-risk individuals. Although not
included in many lists of ideal properties, we must also
be aware of the environmental and safety impact of spent
delivery devices (applicators, vaginal rings, etc.) and
associated packaging. Leeching of API from spent
applicators and vaginal rings and poor-to-no biodegrad-
ability of applicators, boxes, or wrappers could have a
high environmental impact, especially in underdeveloped
settings where disposal is in local or impromptu dumping
sites.
What have we learned from clinical trials of topical
microbicides about formulation of microbicides?
The CAPRISA 004 results heralded a new generation of
microbicide candidates, the ARVs. The CAPRISA 004 trial
results were built upon lessons learned from previous
phases 2b and 3 topical microbicide clinical trials. The
COL-1492 phase 2/3 clinical trial [25] of the microbicide
candidate detergent, nonoxynol-9 (N-9), was the first
microbicide proposed to prevent HIV infection to be tested
for clinical efficacy. When the COL-1492 clinical trial
ended in 2002 (approximately one third of the women in
the trial using the study product greater than 3.5 times a day
had a 50% increase in HIV acquisition), we learned that an
apparently safe contraceptive detergent was not safe when
used as a microbicide to prevent HIV infection. Following
these results, there were a number of in vitro and in vivo
studies that ultimately associated increased infection with
cytotoxicity linked to the detergent properties of N-9 [26].
This led to an understanding that clinical findings in phases
1 and 2 associated with mucosal damage or irritation could
have an impact on virus transmission in later clinical
testing.
The implication that subclinical mucosal damage could
predispose individuals to increased susceptibility to infec-
tion was further suggested by the cellulose sulfate phase 3
clinical trials ([27], two trials: one stopped for potential
harm and the second stopped as a precautionary measure).
Although the final analysis of the cellulose sulfate trials did
not identify a statistically significant increase in HIV
infection, analysis of cellulose sulfate in surrogate in vitro
and in vivo safety and efficacy models suggests that
subclinical toxicities could be the source of the observa-
tions that led to stopping the trial [28–30]. Our knowledge
base for understanding microbicides safety was further
advanced by the National Institute of Allergy and Infectious
Disease-sponsored HIV Prevention Trials Network (HPTN)
035 trial, which defined a safe placebo for use in clinical
testing of topical microbicides [31, 32]. The HPTN 035 trial
incorporated both a condom alone and a placebo arm and
showed that the placebo neither protected against nor
enhanced HIV acquisition. The placebo, which has been
identified interchangeably as the hydroxyethyl cellulose
placebo or universal placebo, was specifically designed to
have minimal impact on the female genital tract and
showed that it is possible to design a formulation with
minimal impact on the female genital tract. Thus, before
evidence of clinical efficacy with CAPRISA 004 was
obtained, clinical studies had identified two critical facts
needed to inform on selection and development of micro-
bicide delivery systems: (1) minor perturbations in the
integrity and function of the mucosa could be the source of
increased susceptibility to infection and (2) identification of
a placebo vehicle that has no detectable clinical impact on
safety or HIV infection.
Another critical issue arising from microbicide clinical
experience has been participant adherence to the micro-
bicide dosing regimen. This has taken two forms: overuse
and under use. In COL-1492, increased transmission was
the result of women using the microbicide >3.5 times a day,
which was consistent with the coital frequency in the
commercial sex worker populations enrolled in the trial.
However, subsequent microbicide trials enrolling a smaller
proportion of commercial sex workers or not using this
population have encountered low adherence as a significant
issue to measuring product efficacy. In the Carraguard
phase 3 clinical trial [33], it was found that adherence (use
verified by staining of returned/used applicators) was much
less than expected (~42%). In contrast, in the HPTN 035
trial with a nonstatistical finding of efficacy (ITT, 33%) for
0.5% PRO2000/5, efficacy appeared to be higher in women
with higher adherence (estimate of 44% for >85% reported
gel and condom use and 78% for high gel /low condom
use) [31].
CAPRISA 004 had similar findings of an association
between use and efficacy (cited above). It must be kept in
mind that that these estimates are derived from a small
portion of the total trial participants and are not statistically
significant. Both the CAPRISA 004 and HPTN 035 trial
had extensive risk reduction counseling to support product
adherence. The above trends identify a potential stumbling
block to determining microbicide clinical efficacy: adher-
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one of the cellulose sulfate trials were reluctant to return
unused gel, even in the context of possible harm, because it
made sex more pleasurable. These results point to a
possible pathway to address product adherence through
adjustment of formulation biophysical and rheological
properties. Although it can only be inferred that low
adherence seen in phases IIB and III trials is a property of
the microbicide vehicle, the lack of significant safety
findings for both 0.5% PRO2000/5 and Carraguard appears
to support this hypothesis. As mentioned above, the
necessary connections between user perception and product
acceptability are now being made [24].
Adherence can also be addressed by selection of micro-
bicide delivery vehicles that disassociate the use of the
microbicide from sexual intercourse. There is currently a lot
of hope for coital-disassociated prevention methods such as
intravaginal rings (IVR). If used properly and consistently, it
is thought that IVRs could increase microbicide adherence
leading togreater efficacythrough moreconvenientuse ofthe
microbicide. However, anecdotal information regarding re-
moval and cleaning of IVRs during menses (loss of drug
coverage and potential hydration of the IVR), expulsion
during bowel movements (sanitary issues), feeling the IVR
during intercourse (loss of stealth, possible removal prior to
intercourse), and the resistanceofsomewomen toconsider an
IVR for prevention suggest that the impact of IVRs on
adherence may be more complicated than originally thought.
It also highlights the need for the development of multiple
delivery approaches that would meet distinct consumer
preferences. Furthermore (at the time this review was written)
although pharmacokinetic studies in NHP and humans
suggest that IVRs might deliver microbicides at concentra-
tions several magnitudes above their 50% in vitro effective
concentrations, biological plausibility for an IVR-delivered
microbicide in NHP to prevent acquisition of SHIV/SIV has
yet to be demonstrated.
HIV infection and formulation
Despite more than 25 years of research, we still have a
number of critical unanswered questions regarding the
mechanism of HIV infection in the genital, penile, and
rectal mucosa. What we understand about HIV transmis-
sion and infection in the context of formulation has
recently been reviewed in a supplemental issue of the
journal: Antiviral Research [34]. This issue summarizes
some of the emerging issues associated with formulation
a n dd e l i v e r yo fm i c r o b i c i d e st op r e v e n tH I Vt r a n s m i s s i o n
discussed at a workshop conducted by CONRAD on
Trends in Microbicide Formulations (January 25–26,
2010).
As we have begun to understand the biology of HIV
infection and transmission, we are also gaining insights into
the rheological and biological properties required to
develop a potentially safe and efficacious topical micro-
bicide delivery strategy. The laboratories of Drs. A. Haase
[35, 36] and C. Wira et al. [37, 38] have contributed
significantly to our understanding of HIV transmission and
the role of the local mucosal factors in susceptibility to
infection. The Dr. A. Haase model for HIV transmission
proposes a series of steps that focus on the establishment of
a founder population of HIV infected CD4+ T cells in the
mucosa, which through a process involving soluble
immune mediators leads to local amplification and dissem-
ination of the virus from the genital mucosa to local lymph
nodes—as a prelude to establishing systemic infection. The
Dr. C. Wira model addresses the role of genital tract innate
and adaptive immunological factors in susceptibility to HIV
infection and hypothesizes a “window of susceptibility”
arising from hormone-driven control of the immune system
and epithelial cell function during the menstrual cycle. With
mediators produced during the menstrual cycle determining
the activity and integrity of innate and adaptive barriers to
HIV acquisition, both models suggest it is critical that the
microbicide be in the right place at the right time, not only
from the perspective of interrupting amplification of
infected founder populations of CD4+ T cells but also
providing protection when natural defenses to infection
may favor infection. These models suggest that (1) micro-
bicides may not need to inactivate virus before encounter-
ing susceptible cells but may demonstrate effectiveness by
preventing amplification and dissemination of the founder
infection and (2) microbicide delivery strategies that
support retention of the API at or in the mucosal epithelium
may broaden the window of microbicide effectiveness.
Data are also emerging that suggests we may need to
approach formulation strategies designed to increase API
penetration into the epithelium with caution. Recent
observations have shown that semen-mediated neutrali-
zation of vaginal pH increases the movement of HIV
virions in mucous, with the implication that the virus
m a ym o r eq u i c k l yr e a c he p i t h e l i a ls u r f a c e s[ 39, 40].
Additionally, observations of the penetration of HIV virus
into genital (vaginal, penile) mucosa by the laboratory of
Dr. T. Hope have determined that virus movement into and
within the genital epithelial barrier is a diffusion con-
trolled process, where virus appears to passively follow
the same routes as water (T. Hope, Microbicides 2008,
New Delhi India [41]). Thus, although formulation science
has a number of excipient tools that can be used to
facilitate the penetration of the microbicide API to and
through epithelial barriers, caution needs to be used to
assure that we are not trading better delivery for increasing
susceptibility to infection.
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right place at the right time without increasing susceptibility
to HIV infection, formulations and vehicles have begun to
emerge that may facilitate the placement of microbicides for
optimal interactions with incoming HIV. Drs. J. Hanes and
R. Cone at Johns Hopkins University have developed and
characterized an approach to circumvent the barrier
properties of cervical mucus using mucous penetrating
nanoparticles [42]. Nanoparticles coated with low molecu-
lar weight polyethylene glycol are able to freely penetrate
cervical mucus to the slower clearing inner layers of
mucous [43]. Early development of these particles suggests
that the particles have minimal impact on mucous structure
and could provide for longer-lasting protection than
particles that are trapped in the outer, faster turning over
layers of mucous.
Nanotechnology has also been used to stabilize
protein microbicides and facilitate their penetration into
vaginal epithelium [44]. Microbicide developers have
also turned to vaginal ring technologies where a slow
continuous release of microbicide may not only address
adherence issues but may also allow for distribution of
the microbicide throughout genital tract without the issues
inherent in a bolus of microbicide gel [45]. Recent studies
in monkeys reported at M2010 (abstract #40 Nutall et al.)
suggest a rapid and significant distribution of virginally
applied tenofovir to the rectum of monkeys, raising the
potential for dual-compartment protection for heterosex-
ual couples that practice both vaginal and anorectal
intercourse.
Concluding remarks
The results of the HPTN 035 and CAPRISA 004 trials have
shown that it is possible to (1) design a safe delivery vehicle
and(2)useamicrobicidetoreducetheriskofHIVacquisition.
The lessons learned from past microbicide clinical trials and
emerging data on the biological and rheological parameters of
formulations, which may control safety, efficacy, and accept-
ability, have begun to open the door to the next phase of
topicalmicrobicidedevelopment.Inthisphase,wemustfocus
on optimizing the biophysical and rheological properties of
themicrobicideformulationtoachievethebestpossiblesafety
andadherencewhiledeliveringittotherightplace,attheright
time, at an effective concentration.
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